Singular Genomics Systems, Inc. logo

Singular Genomics Systems, Inc. (OMIC)

Delisted
NASDAQ (CM) NASDAQ (CM)
Want to track OMIC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

OMIC is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).
$1.8M Bet On Singular Genomics? Check Out These 3 Stocks Executives Are Buying

$1.8M Bet On Singular Genomics? Check Out These 3 Stocks Executives Are Buying

Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades.

Benzinga | 10 months ago
Singular Genomics Systems, Inc. (OMIC) Q2 2024 Earnings Call Transcript

Singular Genomics Systems, Inc. (OMIC) Q2 2024 Earnings Call Transcript

Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder, Chair and CEO Dalen Meeter - CFO Conference Call Participants Daniel Brennan - TD Cowen Matthew Sykes - Goldman Sachs Operator Greeting. Welcome to the Singular Genomics Second Quarter and Business Update Call.

Seekingalpha | 11 months ago

Singular Genomics Systems, Inc. Profile

Medical Instruments & Supplies Industry
Healthcare Sector
Mr. Andrew Spaventa CEO
NASDAQ (CM) Exchange
US82933R1005 ISIN
United States Country
255 Employees
- Last Dividend
26 Jun 2024 Last Split
- IPO Date

Overview

Singular Genomics Systems, Inc. is a forward-thinking life science technology enterprise dedicated to enhancing scientific and medical advancement through next-generation sequencing and spatial multiomics technologies. Catering to both researchers and clinicians, the company aims to propel the realms of science and medicine into new frontiers. Established in 2016 and stationed in San Diego, California, Singular Genomics Systems, Inc. has made notable strides in the life sciences sector. In a significant development, as of February 21, 2025, the company transitioned from a public entity to a private one, marking a new chapter in its evolution.

Products and Services

  • G4 Instrument and Associated Consumables
  • This revolutionary system is designed to cater to a plethora of applications within the genomics field. The G4 suite comprises the versatile G4 instrument along with a range of consumables tailored for specific genomic analyses. Notably, it includes max read kits for exhaustive single cell sequencing, enabling researchers to delve deeper into the biology of single cells. For detecting rare genetic variants with unparalleled precision, the system offers high-definition sequencing solutions. Gene fusion detection is made efficient through the innovative ring-seq technology, while extended range sequencing allows for broader genomic exploration.

  • PX Instrument and Associated Consumables
  • Focusing on the burgeoning fields of single cell and spatial analysis, the PX instrument provides a powerful tool for detailed cellular mapping and understanding. Accompanied by a suite of consumables, it supports cutting-edge research into the spatial organization and expression patterns of genes within individual cells and complex tissues. This platform empowers researchers to uncover the intricate spatial relationships that dictate cellular function and disease progression, thereby opening new avenues for diagnostics and therapeutic strategies.

Contact Information

Address: 3010 Science Park Road
Phone: 858 333 7830